TriSalus Life Sciences Inc.
TriSalus Life Sciences, Inc. engages in the research, development, and commercialization of drug delivery technology platform and immuno-oncology therapeutics to improve outcomes for patients with difficult-to-treat liver and pancreatic cancers. It offers Pressure Enabled Drug Delivery infusion systems, such as the TriNav infusion system, which is used in transarterial radioembolization and chemo… Read more
TriSalus Life Sciences Inc. (TLSI) - Total Liabilities
Latest total liabilities as of September 2025: $63.19 Million USD
Based on the latest financial reports, TriSalus Life Sciences Inc. (TLSI) has total liabilities worth $63.19 Million USD as of September 2025.
Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
TriSalus Life Sciences Inc. - Total Liabilities Trend (2021–2024)
This chart illustrates how TriSalus Life Sciences Inc.'s total liabilities have evolved over time, based on quarterly financial data. Explore and compare other companies by total liabilities.
TriSalus Life Sciences Inc. Competitors by Total Liabilities
The table below lists competitors of TriSalus Life Sciences Inc. ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Hangzhou Tianyuan Pet Products Co. Ltd. A
SHE:301335
|
China | CN¥1.06 Billion |
|
Kocaer Celik Sanayi ve Ticaret A.S.
IS:KCAER
|
Turkey | TL11.75 Billion |
|
Rana Gruber AS
OL:RANA
|
Norway | Nkr783.91 Million |
|
Axiomtek Co Ltd
TWO:3088
|
Taiwan | NT$2.43 Billion |
|
Syrah Resources Limited
PINK:SRHYY
|
USA | $533.96 Million |
|
Taihan Fiber Optics Co. Ltd
KQ:010170
|
Korea | ₩149.82 Billion |
|
EST Tools Co Ltd
SHE:300488
|
China | CN¥611.13 Million |
Liability Composition Analysis (2021–2024)
This chart breaks down TriSalus Life Sciences Inc.'s total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 3.05 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | -2.36 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 1.73 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how TriSalus Life Sciences Inc.'s debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for TriSalus Life Sciences Inc. (2021–2024)
The table below shows the annual total liabilities of TriSalus Life Sciences Inc. from 2021 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | $49.87 Million | -3.48% |
| 2023-12-31 | $51.66 Million | +50.54% |
| 2022-12-31 | $34.32 Million | +394.94% |
| 2021-12-31 | $6.93 Million | -- |